Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
暂无分享,去创建一个
C. Boni | H. Mouridsen | F. Jänicke | A. Monnier | E. Salminen | M. Dank | A. Płużańska | R. Snyder | M. Dugan | J. A. Verbeek | M. Lassus | J. Apffelstaedt | R. Pérez-Carrión | Y. Sun | H. Sleeboom | B. Staffler | P. P. Bapsy | M. Gershanovich | D. Becquart | H. Chaudri-Ross | R. Smith | J. Verbeek | Yan Sun | Robert Smith | Beatrix Staffler
[1] J. Robertson,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Crivellari,et al. Determination of tamoxifen and its metabolites in the endometrial tissue of long-term treated women. , 2000, European journal of cancer.
[4] W. Rostène,et al. Tibolone actions on normal and breast cancer cells. , 2000, European journal of cancer.
[5] L. Dirix,et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Piccart,et al. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial , 2000 .
[7] H. Gundacker,et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] B. Long,et al. Aromatase inhibitors and their antitumor effects in model systems. , 1999, Endocrine-related cancer.
[9] W. Miller. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. , 1999, Endocrine-related cancer.
[10] M. Piccart,et al. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] D. Grigoryev,et al. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity , 1998, The Journal of Steroid Biochemistry and Molecular Biology.
[12] D. Campos,et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] P. Dombernowsky,et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A Howell,et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] L. Case,et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Wolter,et al. Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen , 1994, Cancer.
[17] V. Gebski,et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] A. Goldhirsch,et al. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate? , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] S. Legha,et al. Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.
[20] H. Muss,et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Schaid,et al. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Mouridsen,et al. Endocrine therapy of advanced breast cancer. , 1988, Acta oncologica.